Literature DB >> 10796623

Vaccines for preventing typhoid fever.

E A Engels1, J Lau.   

Abstract

BACKGROUND: Whole cell vaccines, consisting of relatively crude preparations of Salmonella typhi administered parenterally, are effective but have a high incidence of adverse effects. Two vaccines have been developed more recently. Ty21a (an attenuated strain of S. typhi administered orally) and Vi (the purified bacterial capsule, given parenterally), have appeared less toxic than the older whole cell vaccines and are thought to be equally effective.
OBJECTIVES: The objective of this review was to assess the effects of typhoid fever vaccines. SEARCH STRATEGY: We searched the Cochrane Library, Medline, Index Medicus, Embase and reference lists of articles. SELECTION CRITERIA: Randomised trials comparing typhoid vaccines to other types of vaccine or placebo. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trial quality and extracted data. MAIN
RESULTS: Seventeen studies, involving nearly two million people, were included. For the whole cell vaccines single dose regimens provided significant protection for the first two years. Two dose regimens provided significant protection for five years. For the Ty21a vaccine, both two and three dose regimens provided statistically significant protection for two years. The three dose regimen provided protection in the third and fourth years, but protection was not statistically significant in the fifth year. The Vi vaccine provided protection for two years, but the protection in the third year was not significant. The three year cumulative efficacy of two doses of whole cell vaccines was 73% (95% confidence interval 65-80), three doses of Ty21a was 51%, (95% confidence interval 35 to 63) and one dose of Vi was 55% (95% confidence interval 30 to 71). Data on adverse effects were limited, but indicate that whole cell vaccines are more toxic than the newer Ty21a and Vi vaccines. REVIEWER'S
CONCLUSIONS: The whole cell vaccines provided more prolonged protection than either the Ty21a vaccine or the Vi vaccine. However whole cell vaccines are associated with higher toxicity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10796623     DOI: 10.1002/14651858.CD001261

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  10 in total

1.  An all-inclusive vacation.

Authors:  Tom A Szakacs; Anne E McCarthy
Journal:  CMAJ       Date:  2007-07-03       Impact factor: 8.262

2.  Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.

Authors:  Monjori Mitra; Nitin Shah; Apurba Ghosh; Suparna Chatterjee; Iqbal Kaur; Nisha Bhattacharya; Suparna Basu
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

3.  The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization.

Authors:  Thomas A Russo; Janet M Beanan; Ruth Olson; Ulrike MacDonald; Andrew D Cox; Frank St Michael; Evgeny V Vinogradov; Brad Spellberg; Nicole R Luke-Marshall; Anthony A Campagnari
Journal:  Infect Immun       Date:  2013-01-07       Impact factor: 3.441

Review 4.  Will there ever be a universal Staphylococcus aureus vaccine?

Authors:  Gerald B Pier
Journal:  Hum Vaccin Immunother       Date:  2013-06-21       Impact factor: 3.452

5.  Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens.

Authors:  Colette Cywes-Bentley; David Skurnik; Tanweer Zaidi; Damien Roux; Rosane B Deoliveira; Wendy S Garrett; Xi Lu; Jennifer O'Malley; Kathryn Kinzel; Tauqeer Zaidi; Astrid Rey; Christophe Perrin; Raina N Fichorova; Alexander K K Kayatani; Tomas Maira-Litràn; Marina L Gening; Yury E Tsvetkov; Nikolay E Nifantiev; Lauren O Bakaletz; Stephen I Pelton; Douglas T Golenbock; Gerald B Pier
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-28       Impact factor: 11.205

6.  Development of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar Typhi Vi polysaccharide.

Authors:  Herman F Staats; Shaun M Kirwan; Carol C Whisnant; James L Stephenson; Diane K Wagener; Partha P Majumder
Journal:  Clin Vaccine Immunol       Date:  2010-01-27

7.  Gp96 rich lysate as a vaccine candidate against infection with Salmonella typhimurium.

Authors:  N Hosseini Jazani; M Karimzad; S Shahabi
Journal:  Iran J Microbiol       Date:  2010-12

Review 8.  Vaccines for preventing typhoid fever.

Authors:  Rachael Milligan; Mical Paul; Marty Richardson; Ami Neuberger
Journal:  Cochrane Database Syst Rev       Date:  2018-05-31

9.  Review on the Recent Advances on Typhoid Vaccine Development and Challenges Ahead.

Authors:  Khalid Ali Syed; Tarun Saluja; Heeyoun Cho; Amber Hsiao; Hanif Shaikh; T Anh Wartel; Vittal Mogasale; Julia Lynch; Jerome H Kim; Jean-Louis Excler; Sushant Sahastrabuddhe
Journal:  Clin Infect Dis       Date:  2020-07-29       Impact factor: 9.079

10.  Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trial.

Authors:  Anu Kantele; Sari H Pakkanen; Riitta Karttunen; Jussi M Kantele
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.